• Renata Vitoriano Corradi Gomes, A Augusto Peluso, Fernanda Aparecida Ronchi, Lilian Caroline Gonçalves de Oliveira, Dulce Elena Casarini, SantosRobson Augusto SouzaRASDepartment of Physiology, Federal University of Minas Gerais (UFMG), Belo Horizonte-MG, Brazil., Patrick Wander Endlich, and Glaucia Rodrigues de Abreu.
• Mucuri's Medical School, Multicentric Post-Graduate Program in Physiological Sciences and Health Sciences Post-Graduate Program, Federal University of the Jequitinhonha and Mucuri Valleys, Teófilo Otoni-MG, Brazil.
• Am. J. Med. Sci. 2024 Feb 1; 367 (2): 128134128-134.

AbstractCardiovascular diseases (CVD) are the main causes of death in hemodialysis patients, representing a public health challenge. We investigated the effect of different antihypertensive treatments on circulating levels of renin-angiotensin system (RAS) components in end-stage renal disease (ESRD) patients on hemodialysis. ESRD patients were grouped following the prescribed antihypertensive drugs: ß-blocker, ß-blocker+ACEi and ß-blocker+AT1R blocker. ESDR patients under no antihypertensive drug treatment were used as controls. Blood samples were collected before hemodialysis sessions. Enzymatic activities of the angiotensin-converting enzymes ACE and ACE2 were measured through fluorescence assays and plasma concentrations of the peptides Angiotensin II (Ang II) and Angiotensin-(1-7) [Ang-(1-7)] were quantified using mass spectrometry (LC-MS/MS). ACE activity was decreased only in the ß-blocker+ACEi group compared to the ß-blocker+AT1R, while ACE2 activity did not change according to the antihypertensive treatment. Both Ang II and Ang-(1-7) levels also did not change according to the antihypertensive treatment. We concluded that the treatment of ESRD patients on hemodialysis with different antihypertensive drugs do not alter the circulating levels of RAS components.Copyright © 2023. Published by Elsevier Inc.

30 keywords...

hide…